Skip to main content

March 2016

 

 

academics

 

Clinical research courses

HEPATOPROTECTIVE ACTIVITY OF GLIMEPIRIDE BY INDUCING CCL4 HEPATOTOXICITY

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
C.V.H.Hemavathy*, B. Raj kumar, R. Kiran kumar, G. Hema latha

Department of Pharmacy,
Kottam Institute of Pharmacy,
Erravally X Roads, Mahaboob Nagar
*hemarayudu19@gmail.com

ABSTRACT
Hepatoprotective activity of  by inducing ccl4 hepatotoxicity. To study the hepatoprotective activity of against CCL4 induced hepatotoxcity. To evaluate the mechanism of hepatoprotection in terms of Liver antioxidant mechanism, Histopathological study. The animals were divided into Four groups of  three animals each. Except the normal group all the other groups received ccl4 in at a dose of 0.1 ml/kg by intraperitoneally for 14 days. Normal groups received plain tween 80 orally.  On the 14th day all the rats from all the groups were sacrificed, blood was collected from each animal for serum analysis  and their livers were stored  under freezing conditions for the estimation of endogenous anti oxidants and one sample from each group was stored in 10% formalin for histopathological studies.  In bio-chemical studies- Serum analytical methods (AST), (ALT), (Alk.P), (Bil), (TP), (TC). The present findings observed in this study revealed that,glimepirideis natural antioxidant lignin possess significant antioxidant activity against ccl4 induced hepatotoxicity via antioxidant mechanism. However, further research is required to find out the other possible mechanism of hepatoprotection to conform that  as glimepiridehepatoprotective molecule.

WORLD CONGRESS ON DRUG DISCOVERY & DEVELOPMENT - 2016

BioGenesis Health Cluster is pleased to announce the “World Congress on Drug Discovery & Development-2016”, which is scheduled on 18th, 19th& 20th of July, 2016 at J.N.TATA Auditorium, Indian Institute of Science, Bengaluru, Karnataka, India. 

Russian researchers have developed a nanodrug that can identify a brain tumour during the first stage, and can subsequently be used for the diagnosis of other cancer types as well.

(adsbygoogle = window.adsbygoogle || []).push({});

Scientists have developed a new method for harvesting stem cells, which is less invasive and reduces side effects for donors.The new method eliminates the need for the patient to take growth factor injections to increase cell numbers before a transplant.

Novimmune, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NI-0501 for the treatment of patients with primary HLH with refractory disease, or with recurrent or progressive disease during conventional therapy. NI-0501 is a fully human, anti-interferon-gamma (IFNγ) monoclonal antibody discovered and developed by Novimmune.